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A case study is presented. This involves a woman who 
presented with features of hyperthyroidism, which were 
refractory to conventional therapy. She was eventually diagnosed 
to have co-existing coeliac disease and eventually improved on 
a diet excluding gluten. A discussion exploring the association 
between gluten-enetropathy and thyroid dysfunction follows. 
Case presentation
AC, a fifty-year old, previously healthy premenopausal 
woman presented with a six week history of abdominal 
discomfort, and diarrhoea (up to ten times during the day and 
three times during the night). There was also significant weight 
loss: 10 kilograms over the same period. The stools were brown 
coloured and the patient denied rectal bleeding or melaena. The 
appetite was unaffected. The patient also felt very weak and 
depressed. Her appearance was that of a physically weak lady. 
She had exophtalmos of both eyes more marked on the right, 
mildly prominent thyroid gland, and tremor of the outstretched 
hands. Her pulse was 120 beats per minute, regular and of 
good volume. The rest of the examination was unremarkable. 
A diagnosis of thyrotoxicosis was made and the patient was 
started on carbimazole 10mg three times a day and propranolol 
20mg three times a day. Thyroid function tests were taken and 
the results confirmed a hyperthyroid state: Thyroid Stimulating 
Hormone (TSH) was <0.004 uIU/ml (reference range 2.76-
6.45), free thyroxine (FT4) was 64.6 pmol/l (reference range 
10.3-24.45) and free tri-iodothyronine (FT3) was at a level of 17.7 
pmol/l (reference range 2.76-6.45). A full blood count revealed 
a haemoglobin of 11.2 g/dL which is just below the reference 
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range. The Mean Corpuscular Volume (MCV) was 81.5 fL which 
was also slightly below the normal range. Antithyroid antibodies 
(ATA) were 212 IU/mL (reference range <35). 
A week later, the patient came for a follow-up visit. 
Unfortunately in spite of being compliant with treatment her 
clinical condition had not changed. She was still feeling very 
weak and all her symptoms were still present. In particular 
she had lost another two kilograms of weight. A malabsorption 
pathology leading to poor absorption of carbimazole was 
suspected and further investigations were undertaken. 
Screening serological tests for coeliac disease were positive: anti-
tissue transglutaminase (TG) IgG was 2.7U/ml (within reference 
range) but anti-tissue TG IgA was >100 U/ml (values above 
10 are positive) and anti-endomysial IgA (AEA) was reported 
as positive ++. Gastroscopy and duodenal biopsies showed 
increased number of intraepithelial lymphocytes, severe mixed 
inflammatory infiltration of the lamina propria with plasma cell 
predominance, marked villous atrophy and crypt hyperplasia. 
This microscopic picture was consistent with a diagnosis of 
coeliac disease, Marsh‘s Type 3b. 
The patient embarked on a gluten free diet and her symptoms 
started to improve, presumably due to better absorption of 
anti-thyroid medication. An ultrasound of the thyroid revealed 
a nodule in which nuclear imaging showed increased tracer 
uptake. The patient eventually underwent radio–iodine thyroid 
ablation after a 4 month period on carbimazole, progressed to 
hypothyroidism and is on replacement thyroid therapy, together 
with a gluten free diet. She is now totally asymptomatic, has 
regained her lost weight and feels well. 
Discussion
Coeliac disease (CD), also called gluten-induced enteropathy, 
can present in various ways. Patients can present with symptoms, 
signs or even abnormal blood investigations taken as routine or 
for other complaints. There is a high prevalence of undiagnosed 
CD in the general population largely as a result of the many 
atypical manifestations of the disease. The most common 
clinical presentation of CD would be persistent non-specific 
gastrointestinal upset and constitutional symptoms. These 
clinical features are also found in thyroid dysfunction, especially 
thyrotoxicosis. The case history presented above involved a 
lady who presented with full blown features of thyrotoxicosis 
which proved refractory to anti-thyroid medication, possible 
due to malabsorption. CD was diagnosed eventually and the 
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patient finally improved only when her diet excluded gluten-
containing food. 
CD is relatively common in Western populations with a 
prevalence of around 1%.1 However increased prevalence of CD 
has been found in patients with autoimmune thyroid diseases, 
Type 1 diabetes mellitus, autoimmune liver diseases and 
inflammatory bowel disease. Conversely there is also increased 
prevalence of immune based disorders among patients with 
CD. In particular the prevalence of CD in autoimmune thyroid 
disorders was found to be between 2% and 5%1 or approximately 
4-15 times higher than the general population.2 This is not 
altogether surprising given that these conditions share similar 
HLA haplotypes (HLA class II , DqB1*0502 genotype)and are 
associated with the gene encoding cytotoxic T-lymphocyte-
associated antigen-4.1,3 Other immunogenetic theories include: 
antigenic mimicry, damage-induced neoantigen exposure, 
altered intestinal permeability, idiotype network deregulation 
(modification of the immune response by anti-idiotypic 
antibodies) and epitope spreading (development of an immune 
response to epitopes distinct from, and non-cross reactive with, 
the disease-causing epitope).4 Spadaccino et al. demonstrated 
an increased prevalence of CD in adult European and Italian 
patients with auto-immune thyroid disease.5 An IgA deficiency 
is the most frequent immunodeficiency in humans and in 
general high frequency of this disorder was demonstrated in 
those with auto-immune diseases. In a Dutch study, Hadithi et 
al confirmed the association between Hashimoto’s thyroiditis 
and CD.6 Valentino et al. suggested a significant high prevalence 
(3.3%) of CD in patients with autoimmune thyroid disease 
particularly Hashimoto’s thyroiditis.7 Mankai et al. found an 
association between CD and Graves’ disease in a study carried 
out in Tunisia. Caputo et al.reported a case similar to this case 
report where gluten-induced enteropathy was revealed by 
resistance to levothyroxine treatment in a lady with surgically-
induced hypothyroidism.8,9 Another patient had a history of 
thyroid enlargement with normal thyroid function and positive 
anti-peroxidase antibodies. She presented with hypocalcaemia 
after total thyroidectomy and was eventually diagnosed to 
suffer from CD.10 Another patient with idiopathic autoimmune 
hypoparathyroidism who developed hyperthyroidism due to 
Graves disease was subsequently diagnosed with CD. The give-
away clue was malabsorption of L-thyroxine.11 Malabsoption 
to L-thyroxine can be partial and can result in the patient 
needing high doses of L-thyroxine. Silva et al suggested that 
compensation of hypothyroidism requiring doses of L-thyroxine 
in the region of 325µg/day should lead the clinician to actively 
exclude co-existing CD.12 A study from Toulouse suggests 
screening for CD if hypothyroid patients require a daily dose 
above 2 micrograms per kg body weight, whatever their age.13 
Cubiella et al. describe a case which is practically identical to 
the one reported above: the patient was a 65-year old woman 
who presented with CD and autoimmune hyperthyroidism 
simultaneously.14 An interesting study from Turin, Italy found 
that thyroid disease was 3-fold higher in coeliac patients than 
controls.15 In distinct cases, gluten withdrawal reversed the 
thyroid abnormality. 
CD has been associated with T-cell lymphoma of the 
intestine as well as hepatosplenic lymphoma, a specialised 
peripheral type of T cell lymphoma. Freeman reported a case 
where CD was associated with T-cell lymphoma of the thyroid.16 
A study from New York identified an increased risk of papillary 
carcinoma of the thyroid, in patients with CD; the patients were 
following a proper gluten-free diet.17 
Finally a link has been found between CD, panic disorders 
and major depressive disorder. It has been postulated that 
association with subclinical thyroid disease appears to represent 
a significant risk factor for these psychiatric disorders.18 
Several authors are now urging screening for CD in patients 
with thyroid disorders and vice versa. 19-26 Screening for CD 
should include testing for anti-tissue transglutaminase IgG 
and IgA, which is a blood test readily available in Malta. Should 
this be positive (>10.0 units/ml) or weakly positive (6.0-10.0 
units/mL), a duodenal biopsy via gastroscopy should be taken. 
The histopathologist will then confirm or otherwise the diagnosis 
of CD since duodenal biopsy is the gold standard for definite 
diagnosis. In IgA–deficient patients clinical suspicion may 
warrant a duodenal biopsy in spite of negative serological tests 
since false negative results can occur.
Conclusion
There is an association between thyroid disorders and CD. 
When a patient presents with either condition, one should keep 
in mind the possibility of the co-existence of the other. This is true 
especially if thyroid signs and symptoms do not improve with what 
seems to be adequate treatment or if the patient requires much 
higher doses than usual. The lesson to be learnt from this case study 
above is that several diseases frequently co-exist with CD and that 
patients should be screened for several other conditions.
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The Corinthia Group Prize in Paediatrics was awarded to Dr 
Luise Reichmuth, who obtained the highest aggregate mark over the 
combined examinations in Paediatrics in the fourth and final year of the 
undergraduate course. As always, competition for the Corinthia Group 
Prize was fierce, with six candidates vying for the honour!  Whilst offering 
our congratulations to Dr Reichmuth, we would also like to congratulate 
all those undergraduates (now doctors) who performed admirably 
during the undergraduate course in Paediatrics. In the accompanying 
photograph, Dr Reichmuth is seen receiving a cheque for €233 from 
Professor Simon Attard Montalto, Head of Paediatrics at the Medical 
School. Finally, the Academic Department of Paediatrics and Medical 
School remain indebted and are extremely grateful to the Corinthia 
Group for their ongoing support.
Professor Simon Attard Montalto
Corinthia Group Prize in Paediatrics, 2008
